Omalizumab effectively protects against early and late allergic responses in asthma after 4 weeks
J Trischler, A Lieb, M Arnold, J Schulze, M Rosewich… - Allergy, 2017 - Wiley Online Library
J Trischler, A Lieb, M Arnold, J Schulze, M Rosewich, R Schubert, I Bottoli, S Zielen
Allergy, 2017•Wiley Online LibraryBackground Omalizumab is licensed for therapy in severe allergic asthma with an effect
demonstrated after 8 weeks or longer treatment. As new applications for omalizumab
demand precise knowledge of the onset of effects, the objective of this study was to
determine the time course of the early (EAR) and late allergic reaction (LAR). Materials and
Methods Ten patients (IgE> 300 IU/mL and< 700 IU/mL) with a significant response to
allergen challenge were treated with omalizumab according to the approved dosing table …
demonstrated after 8 weeks or longer treatment. As new applications for omalizumab
demand precise knowledge of the onset of effects, the objective of this study was to
determine the time course of the early (EAR) and late allergic reaction (LAR). Materials and
Methods Ten patients (IgE> 300 IU/mL and< 700 IU/mL) with a significant response to
allergen challenge were treated with omalizumab according to the approved dosing table …
Background
Omalizumab is licensed for therapy in severe allergic asthma with an effect demonstrated after 8 weeks or longer treatment. As new applications for omalizumab demand precise knowledge of the onset of effects, the objective of this study was to determine the time course of the early (EAR) and late allergic reaction (LAR).
Materials and Methods
Ten patients (IgE>300 IU/mL and <700 IU/mL) with a significant response to allergen challenge were treated with omalizumab according to the approved dosing table. Bronchial allergen provocations (BAP) were repeated at weeks 1, 2, 4, and 8.
Results
EAR was significantly reduced after 4 weeks (ΔFEV1 28% vs 11%; P<.001), eNO (86 vs 53 ppb; P<.05) and basophil activation after 2 weeks (CD63 expression 79% vs 32%, P<.05) and LAR already after 1 week (ΔFEV1 26% vs 13%, P<.05).
Conclusion
These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy.
Wiley Online Library